Launches BRCA1/BRCA 2 Genetic testing for Hereditary Breast and Ovarian Cancer (HBOC), and Molecular Oncology pipeline for Lung and common cancers~
Mumbai, 27th July 2022: In keeping with its commitment to ensure access to high quality, advanced, and cost-effective diagnostic testing for all, Metropolis Healthcare Ltd. a leading diagnostic service provider today announced the launch of Metropolis Innovation Cell focusing on Molecular Genomics, Superspeciality Pathology and Companion Diagnostics. Under Innovation Cell, Metropolis is introducing various specialized tests related to Pregnancy, Cancer, Infectious Diseases and Transplant Management.
Commenting on the establishment of Metropolis Innovation Cell, Ms. Ameera Shah, Promoter and Managing Director, Metropolis Healthcare Limited said, “As the Innovation and R&D arm of the organization, Metropolis Innovation Cell will focus on the pursuit of fundamental scientific discoveries to catalyze optimal patient management. This in turn will fuel the company’s vision and mission of being the most trusted scientific brand and deliver inner health information with compassion, expertise, and honesty to proactively engage with patient and clinicians. To further our long-term goals in these areas, we will continue to invest in strengthening our scientific capabilities and expanding our infrastructure to serve patients across the country.”
“Metropolis has always been at the forefront in clinical validation of technologies, tests and platforms that directly ensure an accurate timely diagnosis to the patient, including Digital Pathology (Whole Slide Imaging), FDA approved Immunotherapy, targeted therapy biomarkers, liquid biopsy, medical genetics, analytical chemistry, pharmacogenomics, COVID diagnostic & prognostic assays etc. After impacting millions of patients, we want to nurture and expand the scope for Oncology, Prenatal testing, Transplant Immunology, Infectious and Chronic Diseases through Next Generation Sequencing and Artificial Intelligence”, says Dr. Kirti Chadha, Chief Scientific Officer, Metropolis Healthcare Ltd.
Commenting on the launch of new specialised tests, Dr. Ravi Kumar. H.N., VP – Operations (Karnataka) and Chief of Lab, R V Metropolis Healthcare said: “We have a strong track record of introducing specialized tests in the diagnostic industry over the last 40+ years. Our focus is to build our capabilities in different areas and constantly look out for more opportunities to offer ‘affordable’ testing to patients even in tier 2 and tier 3 cities across the country. Karnataka has been one of our key focus states where we have a strong brand presence with 15 labs, and around 80+ patient touch points. The new specialised tests will be available to patients across all our centres in Karnataka and our team will ensure the delivery of accurate and comprehensive results within minimal turnaround timelines.
Dr Ravikumar further added, “Identification of the root cause of any disease is a battle won. That is where the diagnostic sector comes in. At Metropolis, we not only identify the root cause but also study patterns and can suggest preventive measures to curb the situation. Therefore, we constantly engage with clinicians, hospitals, and healthcare industry associations through a series of CMEs, webinars, round table meetings to share and exchange information on diagnosis and tests. With the support of automation and digitization, we facilitate smart reports to clinicians for better and effective clinical decision making.”
